DelveInsight’s “ESR1-mutated Metastatic Breast Cancer – Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Key Highlights ESR1 Mutated Metastatic Breast Cancer Market
Key Companies working in the ESR1 Mutated Metastatic Breast Cancer market are AstraZeneca, Olema Pharmaceuticals, Arvinas, Sermonix Pharmaceuticals, Roche, and many others.
Key Therapies in ESR1 Mutated Metastatic Breast Cancer are Camizestrant, Imlunestrant, H3B-6545, Giredestrant, ARV-471 and many others
In 2022, the market size of ESR1-mutated Metastatic Breast Cancer was the highest in the US among the 7MM, accounting for approximately USD 800 million, which is further expected to increase by 2032.
ESR1 Mutated Metastatic Breast Cancer Overview
In metastatic hormone receptor-positive breast cancer, ESR1 mutations commonly cause acquired resistance to the backbone of therapy and estrogen deprivation by aromatase inhibition. ESR1 mutations rarely occur in primary breast cancer but have a high prevalence in advanced breast cancers previously treated with aromatase inhibitors implying evolution through selective treatment pressure. Most ESR1 mutations occur in hotspot regions in the ligand-binding domain of ER, resulting in ligand-independent, constitutive ER activity. Prior research has demonstrated that circulating tumor DNA (ctDNA) is detected in the plasma of patients with cancer and may provide a robust, noninvasive method for detecting ESR1 mutation.
ESR1 Mutated Metastatic Breast Cancer Epidemiology Insights
Out of all the stage-specific cases, the majority of the patients fall under localized and regional stages of Breast Cancer. ESR1 mutations exclusively occur in HR+-positive patients after an aromatase inhibitor in the metastatic setting.
The total diagnosed prevalent cases of ESR1-mutated Metastatic Breast Cancer in the United States was around 19,000 cases in 2022.
The diagnosed prevalent cases of ESR1-mutated HR+ Metastatic Breast Cancer on first-line of treatment in the United States was estimated to be around 18,000 in 2022.
Among the EU4 countries, Germany had the highest cases of ESR1 mutation in metastatic breast cancer, followed by France, whereas Spain accounted for the lowest number of cases in 2022.
According to DelveInsight estimates, Japan reported approximately 45,000 cases of metastatic breast cancer, equivalent to around 13% of total cases in the 7MM.
According to DelveInsight estimates, the total diagnosed prevalent cases of ESR1-mutated metastatic breast cancer in Japan was approximately 5,000, and these cases are expected to increase during the study period.
Click here to learn more about the ESR1 Mutated Metastatic Breast Cancer Market Landscape
The Report Covers the ESR1 Mutated Metastatic Breast Cancer Epidemiology Segmented by:
ESR1 Mutated Metastatic Breast Cancer prevalent cases
ESR1 Mutated Metastatic Breast Cancer incident cases
ESR1 Mutated Metastatic Breast Cancer treatment cases
ESR1 Mutated Metastatic Breast Cancer diagnosed cases
ESR1 Mutated Metastatic Breast Cancer Market Outlook
SR1 mutations have increased, even with aromatase inhibitor (AI) therapy, indicating their adaptability to AI therapeutic conditions. In addition, the presence of ESR1 mutations has been correlated with a shorter time to treatment failure, as metastatic breast cancer (MBC) patients with ESR1 mutations exhibit an inadequate response to and shorter duration of effective endocrine control. Suppose AI treatment provides selection pressure for mutant-bearing clonal outgrowth in patients. In that case, the next option for therapy is likely a more effective selective estrogen receptor modulator (SERM) and/or selective estrogen receptor downregulators (SERDs). Various studies have predicted that ESR1 mutations will still respond to SERMs or SERDs, though perhaps at a decreased sensitivity based on in vitro, xenograft, and PDX preclinical models. In the past 5 years, agents that have become available are CDK4/6 inhibitors.
Fulvestrant at 500 mg prevents progression in ER mutant-bearing tumors more effectively. This indicates that high-dose fulvestrant may be a promising therapeutic option. It also highlights the need to develop novel, more potent SERMs/SERDs.
Combinations of fulvestrant and other endocrine treatments have not shown a clear advantage over single-agent therapy. However, fulvestrant might offer some advantages compared to other endocrine treatments as an endocrine backbone of combination therapy, most notably the ability to overcome ESR1 mutations that might be seen in patients who have relapsed on or after adjuvant aromatase inhibitors. The majority of patients prefer oral therapy as compared to injectable therapy. However, the drawback of long-term oral endocrine therapy is the lack of treatment adherence.
Key Companies Working in the ESR1 Mutated Metastatic Breast Cancer Market
AstraZeneca,
Olema Pharmaceuticals,
Arvinas,
Sermonix Pharmaceuticals,
Roche,
And many others.
ESR1 Mutated Metastatic Breast Cancer Therapies Covered and Analyzed in the Report
Camizestrant
Imlunestrant
H3B-6545
Giredestrant
ARV-471
And many others
Learn more about the Key Companies and Emerging Therapies in the ESR1 Mutated Metastatic Breast Cancer Market
Table of Contents
Key Insights
ESR1 Mutated Metastatic Breast Cancer Introduction
Executive Summary of ESR1 Mutated Metastatic Breast Cancer
Disease Background and Overview
Epidemiology and patient population
ESR1 Mutated Metastatic Breast Cancer Emerging Therapies
Market Access and Reimbursement of Therapies
Market Drivers
Market Barriers
Appendix
Report Methodology
DelveInsight Capabilities
Disclaimer
Learn about the detailed offerings of the report @ ESR1 Mutated Metastatic Breast Cancer Market Outlook
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Adya KaulEmail: Send EmailPhone: 919650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services
